Skip To Main Content
Philippe Barthelemy on Muck Rack

Philippe Barthelemy

As seen in: Nature, MDPI, The BMJ, ACS Publications, Europe 1, Le journal d'Europe 1, Royal Society of Chemistry, Le Dauphiné libéré, The Lancet, Future Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Philippe

Contact Philippe, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Squamous Cell Carcinoma of the Bladder: Current Evidence, Therapeutic Challenges, and Research Perspectives from the French AVENTUR Group.

|
By Jeremy Mercier, Pierre Cornillon, Philippe Barthelemy
| UroToday Verified
Squamous cell carcinoma (SCC) of the bladder is a rare subtype accounting for 2-5% of bladder cancers in Western countries. Its epidemiology, biological drivers, and clinical behavior differ substantially from urothelial carcinoma (UC), yet most management strategies remain extrapolated from UC due to the absence of dedicated evidence. Robust data are limited, and therapeutic decision-making is challenged by the rarity of this aggressive variant.
Open in Who Shared Issue with article?

Advances in Analysis of Therapeutic Oligonucleotides with Chromatography Coupled to Mass Spectrometry Click to copy article link Article link copied!

|
By Sandy Al Bardawil, Philippe Barthelemy, Ludivine Ferey
| dx.doi.org
Special Issue Published as part of Analytical Chemistry special issue “Fundamental and Applied Reviews in Analytical Chemistry 2026”.
Open in Who Shared Issue with article?

Advances in Analysis of Therapeutic Oligonucleotides with Chromatography Coupled to Mass Spectrometry Click to copy article link Article link copied!

|
By Sandy Al Bardawil, Philippe Barthelemy, Ludivine Ferey
| ACS Publications
Introduction Click to copy section linkSection link copied! Therapeutic oligonucleotides (ONs) have emerged as a promising drug modality for a broad spectrum of diseases, particularly those previously deemed undruggable by small molecules or monoclonal antibodies, such as spinal muscular atrophy, polyneuropathy of hereditary transthyretin-mediated amyloidosis, and acute hepatic porphyria.
Open in Who Shared Issue with article?
See all 25 licensed articles (28 Total)